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Perﬂuorononanoic acid (PFNA) is one of the perﬂuoroalkyl acids found in the environment and in tissues of humans and wildlife.
Prenatal exposure to PFNA negatively impacts survival and development of mice and activates the mouse and human peroxisome
proliferator-activated receptor-alpha (PPARα). In the current study, we used PPARα knockout (KO) and 129S1/SvlmJ wild-type
(WT) mice to investigate the role of PPARα in mediating PFNA-induced in vivo eﬀects. Pregnant KO and WT mice were dosed
orally with water (vehicle control: 10ml/kg), 0.83, 1.1, 1.5, or 2mg/kg PFNA on gestational days (GDs) 1−18 (day of sperm plug
= GD 0). Maternal weight gain, implantation, litter size, and pup weight at birth were unaﬀected in either strain. PFNA exposure
reduced the number of live pups at birth and survival of oﬀspring to weaning in the 1.1 and 2mg/kg groups in WT. Eye opening
wasdelayed(meandelay2.1days)andpupweightatweaningwasreducedinWTpupsat2mg/kg.Thesedevelopmentalendpoints
were not aﬀected in the KO. Relative liver weight was increased in a dose-dependent manner in dams and pups of the WT strain at
alldoselevelsbutonlyslightlyincreasedinthehighestdosegroupintheKOstrain.Insummary,PFNAalteredliverweightofdams
and pups, pup survival, body weight, and development in the WT, while only inducing a slight increase in relative liver weight of
dams and pups at 2mg/kg in KO mice. These results suggest that PPARα is an essential mediator of PFNA-induced developmental
toxicity in the mouse.
1.Introduction
Perﬂuorinated alkyl acids (PFAAs) are a family of chemicals
that have a fatty acid-like carbon backbone saturated with
ﬂuorine and a functional group at the end. They are
surfactants used in many consumer and industrial applica-
tions such as waterprooﬁng and stain repellent on clothing,
carpets, and other fabrics, oil repellent on food packag-
ing, ﬁre-ﬁghting foams, paints, adhesives, hydraulic ﬂuids,
among others [1–4]. Their widespread use in consumer and
industrial products is matched by their global presence in
the environment [2, 5, 6] and in wildlife and humans [7–
12]. The ubiquitous presence of these chemicals, especially
in human sera, has led to concern about their safety. The
two most common PFAAs, perﬂuorooctanoic acid (PFOA)
and perﬂuorooctane sulfonate (PFOS), have been found in
laboratory animals to induce hepatotoxicity, carcinogenicity,
immunotoxicity, disruption of thyroid hormone levels, and
developmental eﬀects including prenatal and neonatal mor-
tality, stunted mammary gland development, developmental
delay, and reduced body weight (reviewed [6, 13]). Although
the manufacture of PFOS was phased out in the United
States and the manufacture of PFOA is being phased out,
alternative PFAAs have been marketed for use.
Perﬂuorononanoicacid(PFNA)isa9-carbonmemberof
the PFAA family found in the environment and in serum at
levelsmuchlowerthanthoseofPFOAorPFOS.Nevertheless,
levels of PFNA in human serum have risen in the last
several years and currently stand at around 1ng/ml [7, 14].
Its presence in human serum has been shown to correlate2 PPAR Research
with PFNA ingested from food and water [15, 16]. Few
studies have investigated its toxicity. In vitro studies found
PFNA to be cytotoxic in HCT-116 cells [17], and hepatotoxic
[18]. PFNA was also found to be immunotoxic in vivo
[19, 20]. More recently, PFNA was found to induce devel-
opmental toxicity in mice when administered throughout
the gestational period [21]. Adverse eﬀects of exposure to
PFNA during gestation include reduced postnatal survival at
5mg/kg/day,delayedeyeopening,delayedpuberty,increased
liver weight, and reduced body weight at 3 and 5mg/kg/day.
One of the mechanisms implicated in the toxicity of the
PFAAs is the activation of peroxisome proliferator-activated
receptor-alpha (PPARα). PPARα is a nuclear receptor that
plays a role in regulating lipid and glucose homeostasis,
cell proliferation and diﬀerentiation, and inﬂammation
[22]. PPARα activation is thought to be responsible for
PFOA-induced hepatotoxicity in rodents [23]a n dc e r t a i n
immunotoxic eﬀects [20, 24, 25]. In addition to PFOA,
a number of other PFAAs activate PPARα in vitro [26–
28]. PPARα may mediate developmental processes, since
PPARα is present during murine development [29]. The
developmental toxicity of PFOA in mice, including neonatal
lethality, delayed eye opening, and reduced body weight,
was found to be dependent on PPARα [30] although
developmental toxicity of PFOS was not [31]. PPARα may
also mediate PFNA eﬀects. Evidence of PPARα activation
was found in livers of mice exposed to PFNA during fetal
development [21]. PFNA also activates PPARα in vitro and
was the most eﬀective of the PFAAs tested in activating both
human and murine PPARα in transfected COS-1 cells [28].
It is therefore logical to postulate that the developmental
toxicity of PFNA, like PFOA, may also be dependent on
PPARα.
In the current study, we sought to determine whether
PFNA-induced developmental toxicity in the mouse requires
expressionofPPARα.Pregnant129S1/SvlmJwild-type(WT)
and PPARα knockout (KO) mice were given PFNA during
gestation, and indices of fertility and neonatal development,
along with serum levels of PFNA, were evaluated. We
report that the developmental eﬀects of PFNA including
pup survival, eye opening, and body weight are dependent
on PPARα and that hepatomegaly is primarily PPARα
dependent but may utilize other pathways as well.
2.MaterialsandMethods
2.1. Animals. Male and female wild-type (WT) 129S1/SvlmJ
mice (stock no. 002448) and PPARα knockout (KO) mice
on a 129S1/SvlmJ background (Ppara-tm1Gonz/J, stock no.
003580) were obtained from Jackson Laboratories (Bar Har-
bor, ME). WT and KO mice were kept in breeding colonies
in the EPA Reproductive Toxicology Facility, Durham, NC.
Colony animals were group housed by sex in Tecniplast cages
(Tecniplast USA, Exton, PA) with Beta-chip hardwood bed-
ding (Northeastern Products, Warrensburg, NY) in a closed
ventilation system, provided pelleted mouse chow (LabDiet
5001, PMI Nutrition International LCC, Brentwood, MO)
and tap water ad libitum, and kept in an atmosphere of
68−74
◦Fa n d4 0 −60% humidity with a 12-hour light-dark
cycle. All animal studies were conducted in accordance
with guidelines established by the USe EPA ORD/NHEERL
Institutional Animal Care and Use Committee. Procedures
and facilities were consistent with the recommendations of
the 1996 NRC “Guide for the Care and Use of Laboratory
Animals”, the Animal Welfare Act, and Public Health Service
Policy on the Humane Care and Use of Laboratory Animals.
2.2. Study Design and Protocol. The study was conducted
in four blocks with WT and KO represented in each block.
WT and KO females were mated overnight to males of
their respective strain, one mating pair per cage. Females
were checked for vaginal plugs the following morning and
plug positive animals were weighed, randomly assigned
to treatment groups, and housed individually in regular
ventilated polypropylene cages. Day of plug was considered
gestationalday(GDs)0.Animalsofeachstrainwereweighed
and dosed by oral gavage once daily on GD 1−18 with either
water (vehicle control: 10ml/kg) or PFNA (CAS# 375-95-
1; 97% pure; Aldrich, St. Louis, MO) at 0.83, 1.1, 1.5, or
2.0mg/kg, based on previous studies with PFNA and PFOA
[21, 30]. Dosing solutions were prepared by dilution, fresh
daily immediately before dosing. At term, adult females
were checked twice daily for the presence of pups. Adult
females with pups or those were pregnant were called dams.
Day of birth was considered postnatal day (PND) 0. Dams
and pups were monitored on a daily basis. The numbers
o fl i v ea n dd e a dp u p sw e r er e c o r d e dt w i c ed a i l y ,a n dl i v e
pups were weighed by sex on postnatal days 0, 1, 2, 3,
7, 10, 14, and 21 (weaning). Pups were monitored for
eye opening daily from PND 11 until all eyes were open.
Eye opening is described as the percentage of pups per
litter having both eyes completely open and was identiﬁed
by technicians trained by demonstration and protocol to
eliminate subjectivity. All animals on study were sacriﬁced
fornecropsyonPND21(42dayspostcoitusfornonpregnant
adult females). Body and liver weights were measured from
each adult female and from 2 pups per litter. Blood was
collected from each dam individually and from all pups
pooled by litter. Serum was extracted and stored at −20
◦C.
Uteri were collected from all adult females, stained with
2% ammonium sulﬁde, and uterine implantation sites were
counted [32].
2.3. Serum Analysis of PFNA. Analysis of PFNA in serum
was performed using a modiﬁcation of a method previously
d e s c r i b e di n[ 33]. For the current study, 25μlo fs e r u mw a s
placed in a 6 ml polypropylene tube, deproteinized with 1ml
of 0.1M formic acid, and vortexed. Two hundred μl of this
mixture was then transferred to a fresh 6ml polypropylene
tube and spiked with 2ml acetonitrile containing 25ng/ml
13C9-PFNA(CambridgeIsotopeLaboratories,Inc.,Andover,
M A ) .T h et u b ew a sv o r t e x e df o r2 0 m i n u t e sa n dt h e n
centrifuged for 3minutes at 3500 rpm to precipitate proteins
or other residue. Two hundred μl of the supernatant was
then transferred to a 500μL polypropylene autosampler
vial and mixed with 200μlo f2Cm Ma m m o n i u ma c e t a t ePPAR Research 3
for HPLC/MS-MS analysis. Solutions were analyzed using
an Agilent 1100 high-performance liquid chromatograph
(Agilent Technology, Palo Alto, CA) coupled with an API
3000 triple quadrupole mass spectrometer (LC/MS-MS;
Applied Biosystems, Foster City, CA). Ten μlo fs o l u t i o n
was injected onto a Luna C18(2) 3×50mm, 5μmc o l u m n
(Phenomenex, Torrance, CA) using a mobile phase consist-
ing of 30% 2mM ammonium acetate solution and 70%
acetonitrile. Peak integrations and areas were determined
using Analyst software (Applied Biosystems Version 1.4.1).
For each analytical batch, matrix-matched calibration curves
were prepared using mouse serum spiked with varying levels
of PFNA (Aldrich, St. Louis, MO). For quality control, check
standards were prepared by spiking large volumes of mouse
serumatseveralarbitrarylevels.Checkstandardswerestored
f r o z e na n da l i q u o t sa n a l y z e dw i t he a c ha n a l y t i c a ls e t .I n
addition, control mouse serum samples were fortiﬁed at two
or three levels in duplicate with known quantities of PFNA
during the preparation of each analytical set. Duplicate
fortiﬁed and several check standards were run in each
analytical batch to assess precision and accuracy. The limit
of quantitation (LOQ) was set as the lowest calibration point
on the standard curve. Analytical batches were considered to
be acceptable if matrix and reagent blanks had no signiﬁcant
PFNA peaks approaching the LOQ, the standard curve had a
correlation coeﬃcient > 0.98, and all standard curve points,
fortiﬁed, and check samples were within 70%−130% of the
theoretical and previously determined values, respectively.
2.4. Data Analysis. Maternal pregnancy, neonatal develop-
ment, and necropsy data were analyzed in GraphPad Prism
(version 4; San Diego, CA). Individual means (maternal
data) or litter means (pup data) and standard errors were
obtained by dose group and strain and analyzed by ANOVA.
Pairwise t-tests were computed within ANOVA to compare
individual treatment groups to relevant control groups
within strain. A Bonferroni multiple-comparison adjust-
ment was used when appropriate. Linear regression analysis
was performed on liver data to detect dose-related trends.
Pregnancy rate was analyzed using chi-square trend analysis.
Litter loss is described as dams that had full litter resorption
(FLR, uterine implants but no pups at birth) or whole litter
loss(WLL,onlydeadpupsatbirth).Litterlosswasexamined
for treatment eﬀect using chi-square analysis. Serum data
were analyzed in SAS for Windows v9.1 (SAS, Cary, NC).
Analyses were performed separately for adult females and for
pups. Adult females were further separated into pregnancy
and lactation status (with live pups or with no live pups
including nonpregnant and litter loss). A subset of dams
matched with their pups was used to determine diﬀerences
in levels of PFNA between dams and pups. Where variances
were heterologous, data were log10 transformed to calculate
means and standard errors and analyzed by ANOVA to
investigate eﬀects of treatment, strain (WT, KO), and block.
WhentreatmentdiﬀerenceswerefoundbyANOVA,pairwise
t-tests between treatment groups were calculatedwithin each
strain and separately by dams or pups, using Tukey-Kramer
adjustment for multiple comparisons where appropriate.
3. Results
3.1. Maternal Pregnancy Outcome and Gestational Body
Weight. Daily maternal body weight and maternal weight
g a i nf r o mG D1t oG D1 8w e r en o ta ﬀected by gestational
PFNA exposure. Implantation and total litter size (live and
dead pups) at birth were not aﬀected in either strain.
However, the number of live pups at birth was signiﬁcantly
reduced in the WT strain at 1.1 (P <.05) and 2.0 (P
<.001)mg/kg PFNA (Table 1) while being not signiﬁcant
at 1.5mg/kg. Percent litter loss was not signiﬁcantly altered
in any dose group in KO or WT although there was a
modest but insigniﬁcant increase in litter loss in the WT
(Table 1). In each dose group in the KO, only 1 or 2 dams
hadFLRorWLLwhile,intheWTgroup,exposed to2mg/kg
PFNA, 4 dams had FLR and 2 had WLL (35% litter loss).
Most dams with FLR did not gain weight comparable to
the pregnant dams that delivered litters, which suggests that
FLR occurred early in gestation. Dams with WLL gained
weight and carried to term, but it cannot be determined by
our protocol whether these pups died prior to delivery or
soonafterdelivery.Pregnancyrate,thepercentageofplugged
mice that had uterine implants, was reduced in treated KO
groups (P<.001) but not in WT groups, suggesting that
PFNA may have interfered with implantation when PPARα
was not functional.
3.2. Pup Survival, Development, and Body Weight. The
reduced viability of pups at birth in the WT at 1.1 and
2mg/kg continued through the postnatal period. Survival
of WT pups from birth to weaning (PND 21) was greatly
reduced at 1.1 (P <.05) and 2 (P <.001)mg/kg PFNA
(Figure 1). By PND 21, survival of pups in the WT 1.1 and
2.0mg/kg groups was reduced to 36% and 31%, respectively.
In contrast, survival was not aﬀected in the KO at any dose.
Eye opening was used as a marker of postnatal develop-
ment. The mean day of eye opening in the controls was PND
13.7 ±0.3inWTandPND13.9 ±0.2inK O .Themeandayof
eyeopening wassigniﬁcantlydelayedat2mg/kgPFNAinthe
WT by two days, to PND 15.8 ± 0.2 (P<. 01), but not at any
other dose. In contrast, the mean day of eye opening was not
aﬀectedatan ydoseinK O .Theper centofeyesopenonPNDs
13, 14, 15, and 16 was also signiﬁcantly reduced in the WT at
2mg/kg PFNA while being not aﬀected in the KO (Figure 2).
Pup birth weight was not aﬀected by any dose of PFNA
in WT or KO, either in males or females (Table 2). Although
pup body weight was not diﬀerent among groups at birth,
p u pb o d yw e i g h tw a sr e d u c e di nb o t hm a l ea n df e m a l eW T
pups in the 2mg/kg group at several time points during the
postnatalperiod,beginning atPND7andincluding weaning
(Figure 3). Weight gain during this period was reduced in
WT female pups from 8.52g in controls to 6.35g in the
2mg/kggroup(P<. 001), but not in male. In contrast, body
weight and weight gain were not aﬀe c t e da ta n ya g ea ta n y
dose level in the KO (Figure 3).
3.3. Liver Weight and Body Weight at PND21. Absolute
liver weight was increased in a dose-dependent fashion in4 PPAR Research
Table 1: Eﬀects of gestational administration (GD 1−18) of PFNA to wild type and PPARαKO mice on maternal weight and reproductive
outcomes.
Strain Dose
(mg/kg/day)
No. of
pregnanta
Maternal
Weight Gain
GD1−18b (g)
Maternal
Weight
GD18b (g)
No. of uterine
implants
Total no. of
Pups per litterc
(live + dead)
No. of live
pups per
litterc
% Litter
lossd
Pregnancy
ratee (%)
WT
01 4 1 0 .8 ± 0.98 34.4 ± 0.88 .5 ± 0.67 .1 ± 0.56 6.8 ± 0.70 14.35 3 .8
0.83 11 12.8 ± 0.81 35.0 ± 1.08 .5 ± 0.66 .8 ± 0.70 6.1 ± 0.82 9.14 7 .8
1.1 12 10.8 ± 0.57 33.6 ± 0.47 .3 ± 0.55 .6 ± 0.50 3.7 ± 0.37
∗ 16.73 5 .3
1.5 14 12.6 ± 0.50 36.0 ± 0.58 .4 ± 0.66 .2 ± 0.54 4.7 ± 0.67 7.13 8 .9
2.0 17 13.2 ± 0.74 35.9 ± 0.97 .8 ± 0.65 .2 ± 0.54 3.1 ± 0.73
∗∗ 35.34 7 .2
KO
01 8 1 2 .0 ± 0.49 35.9 ± 0.68 .9 ± 0.47 .8 ± 0.36 7.0 ± 0.41 11.17 5 .0
0.83 13 11.4 ± 0.73 34.6 ± 0.88 .4 ± 0.67 .2 ± 0.58 7.0 ± 0.54 7.76 5 .0
†
1.1 14 11.5 ± 0.56 35.6 ± 0.69 .2 ± 0.48 .3 ± 0.49 7.8 ± 0.43 7.15 8 .3
†
1.5 9 12.1 ± 0.87 35.5 ± 1.39 .8 ± 0.68 .5 ± 0.80 8.4 ± 0.84 11.12 0 .9
†
2.0 16 11.0 ± 0.80 33.4 ± 0.98 .1 ± 0.76 .6 ± 0.62 6.4 ± 0.66 12.54 3 .2
†
Values are means ± SEM.
KO: PPARα knockout; WT: wild type; GD: gestational day.
aPregnancy veriﬁed by presence of uterine implantation sites.
bExcludes adult females not pregnant or with full litter resorption.
cNumber of pups on day of birth at ﬁrst observation.
dLitter loss: uterine implants present but no pups (full litter resorption) or only dead pups (whole litter loss) at birth.
ePregnancy rate: (# pregnant / # plug +)∗100.
∗P<. 05, ∗∗P<.001 by Bonferroni’s test. †P<. 001 by chi-square test for trend.
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Figure 1: Eﬀects of prenatal exposure to PFNA on survival of wild-type (WT) and PPARα knockout (KO) mouse pups. Data represent
litter means ± SEM of the percent of the litter alive on postnatal days 0−3, 7, 10, 14, 17, and 21. Survival was reduced in WT pups by 1.1
and 2.0mg/kg PFNA on GDs 1−18. Asterisks denote a signiﬁcant diﬀerence (P<. 001) found by ANOVA and Bonferroni’s test for multiple
comparisons. PND: postnatal day.
all PFNA-treated groups in WT adult females, regardless
of prior pregnancy status. In KO adult females, however,
liver weight was not aﬀected by PFNA in dams but was
increasedinthe1.5and2.0mg/kggroupsinthenonpregnant
adult (Table 3). In addition, among the nonpregnant adults,
the dose dependent increase in liver weight was lower in
KO compared to WT (P<. 0001, by regression analysis).
Similarly, relative liver weight was increased in a dose-
dependentfashioninalltreatedgroupsintheWT(P<. 001),
regardless of pregnancy history, and in 1.1mg/kg and higherPPAR Research 5
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Figure 2: Eﬀect of prenatal exposure to PFNA on the percent of eyes open on postnatal days 13−16 in wild-type (WT) and PPARα knockout
(KO) mouse pups. Data represent litter means ± SEM of the percent of the litter with pups having both eyes fully open. A reduction in the
percent of eyes open was found in the WT pups exposed to 2mg/kg PFNA. Diﬀerences were found by ANOVA and Bonferroni’s test for
multiple comparisons. Asterisks denote a signiﬁcant diﬀerence (∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 0001). PND: postnatal day.
Table 2: Birth weights of wild type and PPARα KO mouse pups
after in utero exposure to PFNA on GD 1−18.
Dose
(mg/kg/day)
n Male weight
(g)
n Female weight
(g)
WT
0 11 1.28 ± 0.03 12 1.26 ± 0.03
0.83 8 1.28 ± 0.03 10 1.30 ± 0.05
1.1 10 1.29 ± 0.06 10 1.34 ± 0.06
1.5 11 1.33 ± 0.03 12 1.32 ± 0.03
2.0 9 1.41 ± 0.06 8 1.30 ± 0.05
KO
0 16 1.24 ± 0.03 16 1.19 ± 0.02
0.83 12 1.28 ± 0.03 12 1.25 ± 0.03
1.1 12 1.25 ± 0.04 13 1.20 ± 0.03
1.5 8 1.20 ± 0.04 8 1.15 ± 0.04
2.0 10 1.26 ± 0.03 14 1.29 ± 0.05
Values are litter means ± SEM. n:n o .o fl i t t e r s .W T :w i l dt y p e ;K O :P P A R α
knockout; n:n u m b e ro fl i t t e r s .
doses in the nonpregnant KO (Figure 4). In KO adults that
hadbeenpregnant,relativeliverweightwasunaﬀected.Body
weight at necropsy was generally unaﬀected by dose or strain
(Table 3). Absolute liver weight was increased in all PFNA
dose groups in WT pups but was unaﬀected in KO. Relative
liver weight was increased in all dose groups in WT pups but
in only the highest dose group, 2mg/kg, in KO (Figure 4).
Body weight was not reduced in KO pups at any dose. Pup
body weight was reduced in WT at 2 mg/kg only (Table 3).
3.4. Serum PFNA Levels. PFNA was detected in serum of all
animals (Table 4). PFNA levels were signiﬁcantly higher in
PFNA-treated mice at every dose level compared to controls
(P<. 0001)andlevelsincreasedinadose-dependentfashion.
Serum PFNA levels were higher in adult females with no
live pups (regardless of pregnancy) compared to adults with
live pups by P<.001 (KO) and P<.005 (WT). PFNA levels
were also higher in pups compared to their dams, based on
a subset of dams matched to their existing pups at weaning
(KO, P<.0001; WT, P<.005). In all dams with nursing pups,
PFNA levels were lower in KO compared to WT (P<.001)
while, in pups, PFNA levels were higher in KO compared to
WT (P<.0001; Table 4).
4. Discussion
Perﬂuorononanoic acid (PFNA) has recently been shown
to induce developmental toxicity and liver enlargement in
mice [21], as do other perﬂuoroalkyl acids. The purpose
of the current study was to determine whether these eﬀects
are dependent on PPARα, using the 129S/SvlmJ PPARα
knockout (KO) mouse model. Gestational exposure to
PFNA reduced neonatal survival and body weight through
the weaning period, delayed eye opening, and increased
absolute liver weight in the WT oﬀspring at doses as low
as 0.83mg/kg/day. By contrast, these eﬀects were not seen
in KO oﬀspring. These ﬁndings demonstrate that PFNA is
a developmental toxicant and its eﬀects are dependent on
expression of PPARα.
This pattern of reduced survival, body weight, delayed
development, and increased liver weight is common to most
perﬂuoroalkyl acids (PFAAs) studied thus far. These eﬀects
have been reported in rodents for PFOA [30, 34], PFOS,
[31, 35, 36], and PFNA [[21, 37], Das, 2010 #389], with a few
speciﬁcdiﬀerencesthatmaybeduetostrain,dosingregimen,
and the chain length and functional group of the PFAA. Such6 PPAR Research
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Figure 3: Eﬀects of prenatal exposure to PFNA on postnatal body weights of wild-type (a, b) and PPARα knockout (c, d) male (a, c) and
female (b, d) pups. Data represent litter means ± SEM on postnatal days 0−3, 7, 10, 14, 17, and 21. Body weights of WT pups were reduced
by 2 mg/kg PFNA on postnatal days 7, 10, and 14, in male pups and days 7−21 in females. No eﬀect on body weight was found in KO pups.
Signiﬁcant diﬀerences were found by ANOVA, and diﬀerences between groups were found by Bonferroni’s test for multiple comparisons.
Asterisks denote a signiﬁcant diﬀerence (∗P<. 05 by t-test, ∗∗ P<. 01, ∗∗∗ P<. 001).
studiesalsoobtainedeﬀectsinoﬀspringatdoselevelsthatare
not maternally toxic [30, 31, 34, 35, 38], as shown here. Also
common to the current and previous studies, the liver was
the most sensitive target tissue, with eﬀects on liver weight
seen in both WT dam and pup from the lowest dose level
of PFNA used in the study, 0.83mg/kg, and higher. Reduced
survival, body weight, and delayed eye opening in pups were
also sensitive endpoints, inducing eﬀects at the next higher
dose levels, 1.1 and/or 2.0mg/kg. Survival and number of
live pups at birth were compromised at 1.5mg/kg, but the
values did not reach statistical signiﬁcance. The reason for
this ﬁnding is unclear. The serum PFNA concentrations
and the liver weight in the pups in this dose group were
in the expected ranges for a linear dose-response curve,
suggesting proper dose preparation and administration for
1.5mg/kg. In addition, the “n” of 12litters in this treatment
group was comparable to that of other dose groups, so it
seems unlikely that the outcome is related to a low statisticalPPAR Research 7
Table 3: Liver and body weights (grams) of wild type and PPARα-KO adult females and pups at necropsy (PND 21) after exposure to PFNA
on GD 1−18.
Strain Dose (mg/kg/ day) Adult females (NP) Adult females (P) Pups (sexes combined)
Liver Weight Body Weight Liver Weight Body Weighta Liver Weight Body Weight
00 .86 ± 0.03 22.7 ± 0.42 1.52 ± 0.87 27.3 ± 0.58 0.381 ± 0.02 9.62 ± 0.36
0.83 1.49 ± 0.04
∗∗ 22.9 ± 0.48 1.65 ± 0.07 26.4 ± 0.56 0.551 ± 0.03
∗∗ 9.79 ± 0.30
WT 1.1 1.80 ± 0.04
∗∗ 24.0 ± 0.43 1.91 ± 0.10
∗ 26.2 ± 0.72 0.649 ± 0.05
∗∗ 10.34 ± 0.61
1.5 1.86 ± 0.05
∗∗ 23.0 ± 0.56 2.24 ± 0.05
∗∗ 28.2 ± 0.66 0.608 ± 0.02
∗∗ 9.47 ± 0.23
2.0 2.18 ± 0.04
∗∗ 24.2 ± 0.36 2.51 ± 0.07
∗∗ 27.5 ± 0.70 0.518 ± 0.01
∗∗ 7.56 ± 0.42
∗∗
00 .99 ± 0.04 24.8 ± 0.74 1.88 ± 0.06 29.1 ± 0.32 0.417 ± 0.01 9.35 ± 0.19
0.83 1.20 ± 0.04 24.7 ± 1.00 1.77 ± 0.06 28.3 ± 0.38 0.421 ± 0.01 9.16 ± 0.28
KO 1.1 1.17 ± 0.07 23.2 ± 0.54 2.02 ± 0.05 29.6 ± 0.40 0.429 ± 0.02 9.18 ± 0.26
1.5 1.45 ± 0.04
∗∗ 23.8 ± 0.41 1.74 ± 0.16 26.2 ± 1.32
∗ 0.422 ± 0.02 8.51 ± 0.34
2.0 1.53 ± 0.04
∗∗ 23.4 ± 0.28 1.96 ± 0.10 28.0 ± 0.77 0.489 ± 0.03 8.98 ± 0.40
Values are means ± SEM.
Pup weights were on 2 pups per litter. NP: not pregnant; P: pregnant; WT: wild type; KO: PPARα knockout; Wt: weight.
NP includes those with full litter resorption and no weight gain; P includes those who gave birth whether pups were live or dead.
aP<. 05 compared to NP females body weight. ∗P<. 05, ∗∗P<. 001 compared to controls within column and strain. See text for other comparisons.
Table 4: Serum PFNA concentrations at weaning in PPARα-KO and WT Adult female mice and oﬀspring exposed to PFNA on GD 1−18.
Strain Dose (mg/kg/day) Adult females with no live pups Adult females with live pups Pups (sexes combined)
n PFNA (μg/ml) n PFNA (μg/ml) n litters PFNA (μg/ml)
01 4 0 .067 ± 0.005 12 0.022 ± 0.004 9 0.033 ± 0.008
0.83 13 28.5 ± 1.22a 10 8.91 ± 1.51a 89 .60 ± 9.37a
WT 1.1 26 39.7 ± 1.26a 10 23.2 ± 2.57a 51 5 .7 ± 1.42a
1.5 23 48.4 ± 1.54a 13 21.0 ± 3.01a 10 17.5 ± 1.15a
2.0 26 64.0 ± 2.46a 11 35.3 ± 3.90a 72 5 .3 ± 2.70a
09 0 .048 ± 0.008 16 0.016 ± 0.001 16 0.068 ± 0.027
0.83 8 38.4 ± 2.34a 11 2.76 ± 0.172a 12 15.2 ± 1.01a
KO 1.1 11 53.9 ± 2.51a 13 4.17 ± 0.310a 12 19.4 ± 0.69a
1.5 37 72.1 ± 2.91a 81 1 .8 ± 5.71a 72 6 .4 ± 1.39a
2.0 23 83.4 ± 2.93a 15 22.6 ± 5.69a 12 38.4 ± 1.80a
Values are means ± SEM or litter means ± SEM. Serum was collected from all adult females and from 2 pups per litter at 23 days post dose.
WT: wild type; KO: PPARα knockout.
a Signiﬁcantly diﬀerent from control values by P<. 0001. See text for more statistical comparisons.
power. Thus, the lack of consistent eﬀect on survival cannot
be explained and may simply reﬂect biological variabil-
ity. Nonetheless, all developmental endpoints were clearly
PPARα dependent. The dependence of the developmental
eﬀectsofPFNAonPPARαisnotunique,asthishasalsobeen
demonstrated previously for PFOA [30]. However, not all
PFAAsdependuponPPARαtoinducedevelopmentaleﬀects.
The developmental eﬀects of PFOS, for example, were not
found to be dependent on PPARα [31]. This may be due
to the sulfonated head group of PFOS, and thus PPARα
dependence may be a feature of the perﬂuorocarboxylic
acids.
Mode of action diﬀerences between the perﬂuorinated
carboxylic acids, PFOA and PFNA, and the sulfonate PFOS
may also be evident in the pattern of neonatal loss observed
following exposure to these compounds. PFNA exposure in
WT mice resulted in a drastically reduced number of viable
pups at birth with a continued loss of pups within the ﬁrst
few days, followed by a gradual loss until PND 10. Similarly,
PFOA induced a sudden loss of viable pups within the ﬁrst
few days of life, with a gradual loss over 10 days in CD-
1m i c e[ 38] and 14 days in the 129S/SvlmJ strain [30]. In
contrast to our study, PFNA in CD-1 mice induced a gradual
loss of pups over the course of 12 days with no signiﬁcant
loss at birth [21]. This diﬀerence may be due to the increased
sensitivity of the 129S/SvlmJ strain. Although survival curves
for PFOA and PFNA can follow a course of up to 10−14
days, in utero exposure to PFOS results in a sudden loss of
viabilityinpupswithintheﬁrstfewhoursafterbirththrough
postnatal day 2 in the rat [35, 36] .T h e s ep u p sw e r eo b s e r v e d
to be in respiratory distress and displayed poor inﬂation of
the lungs [36, 39] although the precise mechanism has not
beenfound.ThistwodaylossofpupsafterexposuretoPFOS
was observed in the 129S/SvlmJ strain as well, and only in
KO did a few more die as late as PND 10 [31]. Therefore,
in neonates, PFNA may be utilizing the same mechanism of
action as other perﬂuorinated carboxylates while sulfonates
such as PFOS utilize another.8 PPAR Research
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Figure 4: Eﬀects of gestational exposure to PFNA on relative liver weight of the wild-type (WT) and PPARα knockout (KO) nonpregnant
adult female (a) dams (b) and pups (c) Measurements were taken on all individual adult females and on two pups per litter at weaning (i.e.,
23 days after last dose or postnatal day 21). Data represent means or litter means ±SEM. Relative liver weight was calculated as the absolute
liverweight/bodyweight ×100foreachdatapoint.RelativeliverweightwasincreasedbyPFNAexposureinbothpregnantandnon-pregnant
adults and pups in all treated groups in the WT while only in the nonpregnant adult KO at 1.1 to 2mg/kg and in the KO pup at 2.0mg/kg.
Signiﬁcant diﬀerences were found by ANOVA, and diﬀerences between groups were found by Bonferroni’s test for multiple comparisons.
Asterisks denote signiﬁcant diﬀerences compared to controls (∗P<. 05, ∗∗ P<. 001).
In the liver, there appear to be PPARα-independent as
wellasPPARα-dependenteventsinresponsetoPFNA.PFNA
was found to increase relative and absolute liver weight in
the WT adult, but to a lesser extent in the nonpregnant KO,
and not at all in the pregnant KO adult. The lack of eﬀect on
liver weight in the pregnant KO may suggest that the eﬀects
of PFNA on liver weight in adult KO mice are modest and
weremaskedbytheincreaseinliverweightduetopregnancy.
The attenuated response in the KO liver compared to the
WT liver is more obvious in the pup and may imply a
separate, less eﬃcient mechanism independent of PPARα.
Similarly, less robust eﬀects on liver weight in KO compared
to WT mice were observed after exposure to PFOA [30].
Histopathological examination of those livers revealed a dif-
ference in histology of treated KO livers compared to treated
WT livers [40], suggesting a diﬀerent mechanism in KO
mice. Other pathways suggested have included constitutive
androstane receptor (CAR) and pregnane X receptor (PXR)
[41–43], both present in humans. Therefore, PFNA may
primarily utilize PPARα to increase liver weight while relying
upon other pathways in the absence of PPARα.I n v o l v e m e n t
of PPARα in the liver may be a mechanism utilized by
other PFAAs, since perﬂuorobutyrate also increased liver
weight and induced hepatocyte hypertrophy dependent onPPAR Research 9
PPARα [44]. Relevance of the PPARα mechanism to humans
has been criticized primarily based on the lower number
of these receptors in the liver of human versus mouse.
However, PPARα is implicated here in the developmental
eﬀects of PFNA as well, and the etiology of PPARα in other
tissues of the embryo, fetus and neonate of the human
and the mouse that are involved in gross development has
not been fully determined. Therefore, the possibility of
relevance of PPARα to a human response to PFNA cannot
be dismissed.
The levels of PFNA in the serum of pups, nursing dams,
and adult females with no pups illustrate some interesting
ﬁndings. First, the dose-dependent serum levels of PFNA
in all groups of animals reﬂect the dose-dependent eﬀects
observed in dams and pups. Second, the eﬀects observed in
WT pups were not due to higher concentrations of PFNA in
their system, since serum levels of PFNA were actually lower
in WT pups than in KO pups at all doses. Conversely, the
general lack of developmental eﬀects in KO pups was not
due to impaired pharmacokinetic distribution of PFNA to
the pup. Another important observation is the possibility of
substantial transfer of PFNA from dam to pup through milk.
PFNA can enter milk, as evidenced by the ﬁnding of PFNA
in the milk of humans [45–47], rats [48], and mice [49].
The lower serum PFNA levels in lactating dams compared to
nonlactating adultfemalesatweaning suggestanelimination
of PFNA from the dams through placental transfer and
through the milk. In addition, PFNA levels were elevated in
pups compared to their mothers. This has also been reported
for PFOA, in which an increased body burden was observed
in the pups from birth to postnatal day 8 [49]. However, the
contribution of placental versus lactational transfer of PFNA
cannot be determined by the design of this study. Serum
levels of PFNA in this mouse model were much higher than
those of humans [7] but were measured to compare with the
physiological eﬀects observed and not to compare to human
levels.
PFNA was found in this study to be a liver and
developmental toxicant comparable in strength to other
PFAAs, as adverse responses were elicited at maternal doses
as low as 0.83mg/kg. In the CD-1 mouse, PFNA appears
to be more potent than PFOA. PFNA reduced CD-1 pup
survival at 5mg/kg/day, compared to10mg/kg/day by PFOA,
and delayed eye opening at 3mg/kg/day compared to
5mg/kg/day by PFO A [21, 34, 37, 38]. In vitro analysis of
PPARαactivationshowsPFNAtobemorepotentthanPFOA
as well [28]. The 129S strain used in the current study was
used as an animal model for investigating mechanisms of
action rather than for relative potency, as toxicity and PBPK
data are lacking and this strain appears to be more sensitive
to PFAAs. It is also clear that PFNA is more potent than
PFOS. PFOS induced a 50% reduction in survival in CD-
1o ﬀspring at 10mg/kg/day [35] and at 8.5mg/kg/day in
129S/SvlmJ mice [31] whereas PFNA reduced survival at
1.1mg/kg/day in the current study or 5mg/kg in CD-1 mice.
Given the lower activity of the sulfonated PFAA compared
to the carboxylated PFAA on PPARα in vitro [28], lower
potency in vivo may be expected for other sulfonated PFAAs
as well.
5. Conclusion
I ns u m m a r y ,P F N Ai sad e v e l o p m e n t a lt o x i c a n ti nm i c e ,a n d
the developmental eﬀects are dependent upon expression
of PPARα. The general pattern of eﬀects observed in the
mouse after gestational PFNA exposure mirrors the eﬀects
of other PFAAs, most closely that of PFOA. In addition, the
diﬀerential response to PFNA in the livers of WT and KO
adult females suggests a PPARα-dependent mode of action
for increased liver weight, although additional pathways and
mechanisms appear to be involved.
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